कंपनी का अवलोकन
LeonaBio, Inc. is a clinical-stage biopharmaceutical enterprise dedicated to the development of small molecules designed to restore neuronal health and decelerate the process of neurodegeneration. The company operates within the healthcare sector, specifically the biotechnology industry, where it leverages scientific research to create therapeutic interventions for serious neurological conditions. Its current valuation is represented by a market capitalization of $89.61M, while its annual revenue remains unreported as TTM data is not available, and the employee count is listed as N/A. These financial figures indicate that the company is a small-cap entity with limited revenue visibility, suggesting it is likely in a capital-intensive research and development phase typical of early-stage biotechnology firms. The absence of reported revenue and employee metrics further contextualizes the company's position as a pre-commercial entity focused entirely on advancing its clinical pipeline rather than generating immediate sales.
वित्तीय स्वास्थ्य
The company reports a net income of $-105,609,000 and an EBITDA of $-33,206,000, while revenue figures are not available for the trailing twelve months. The significant disparity between the unreported revenue and the substantial negative net income reveals a cost structure dominated by high operating expenses associated with clinical trials and research, rather than traditional cost of goods sold. Despite the negative net income, the company maintains a positive free cash flow of $22.47M, which provides essential financial flexibility to fund ongoing operations and clinical development without immediate reliance on external financing. All three margins—gross margin, operating margin, and profit margin—are recorded at 0.0%, indicating that the company has not yet achieved profitability or that margins are negligible due to the developmental stage of the business. The balance sheet holds $88.33M in cash against a debt liability of $803,000, resulting in a debt-to-equity ratio of 2.89, which suggests a leveraged position despite the low absolute debt level. The current ratio stands at 1.88, indicating that the company possesses sufficient liquid assets to cover its short-term obligations, thereby ensuring short-term liquidity stability. Furthermore, the return on equity is -290.8% and the return on assets is -28.3%, metrics that reveal management is currently deploying capital to generate losses rather than returns, which is expected for a clinical-stage company but highlights the high risk profile of the equity investment.
मूल्यांकन आकलन
Trailing P/E and forward P/E ratios are both listed as N/A, implying that the absence of earnings data prevents the calculation of traditional price-to-earnings multiples and suggests the market cannot value the stock based on current or expected profitability. The price-to-book ratio is 1.83, which indicates that the market is valuing the company at a premium of 83% over its net asset book value, reflecting potential optimism regarding the success of its clinical pipeline or the intrinsic value of its intellectual property. Price-to-sales and EV/EBITDA metrics are either unavailable or negative, with an EV/EBITDA of -0.06, suggesting that alternative valuation methods are distorted by the company's lack of profitability and the absence of sales data. The stock has traded between a 52-week low of $2.20 and a 52-week high of $14.21, meaning the current trading price sits within a wide volatility range that reflects the speculative nature of the asset. The beta value is 2.23, which signifies that the stock price is highly volatile and expected to fluctuate with significantly higher magnitude than the broader market, exposing investors to amplified systematic risk.
Growth & Income
Revenue growth and earnings growth rates are both listed as N/A, preventing any quantitative comparison of how earnings are growing relative to revenue or providing insight into the company's historical expansion trajectory. As a non-dividend payer, the company does not offer a dividend yield or a payout ratio, as the payout ratio is 0.0%, indicating that all available earnings are retained within the company to fund its research and development activities rather than being distributed to shareholders. This reinvestment strategy is standard for clinical-stage biotechnology firms, where capital must be directed toward advancing assets through clinical trials to eventually achieve commercialization. Consequently, the overall growth and income profile of LeonaBio, Inc. is characterized by a complete reliance on internal capital generation and external financing to drive future value, with no current income stream for investors.